Frontida BioPharm, a Philadelphia, Pennsylvania-headquartered contract development and manufacturing organization, has signed a pact with Oncoceutics, a Philadelphia-headquartered clinical-stage drug discovery and development company, to further develop and scale up the finished product manufacturing process for ONC201, Oncoceutics’ lead molecule.

ONC201 is an antagonist of the G-protein coupled receptor dopamine receptor D2 and is designed to target this receptor specifically for oncology. The drug is currently in Phase II clinical trials for select advanced cancers, including multiple trials in high-grade gliomas.

Under this agreement, Frontida will manufacture the NC201 drug product in its GMP certified facilities for clinical trials and future commercial purpose. Frontida has also made an equity investment in Oncoceutics.

Source: Frontida BioPharm